Radiation therapy in the locoregional treatment of triple-negative breast cancer

The Lancet Oncology

Volumn 16, Issue 3, 2015, Pages e113-e122

  Moran, Meena S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; STEM CELL FACTOR; TRASTUZUMAB; TUMOR MARKER;

CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HOMOLOGOUS RECOMBINATION; HUMAN; IMMUNOHISTOCHEMISTRY; LOCAL RECURRENCE FREE SURVIVAL; MASTECTOMY; MOLECULAR TYPING; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; TP53 GENE; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; WHOLE BODY RADIATION; ADJUVANT THERAPY; CHEMISTRY; DECISION SUPPORT SYSTEM; FEMALE; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY; PATIENT SELECTION; PHENOTYPE; PREDICTIVE VALUE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR RECURRENCE;

DECISION SUPPORT TECHNIQUES; DOSE FRACTIONATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASTECTOMY; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RADIATION TOLERANCE; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84924853899     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71104-0     Document Type: Review

References (71)

1. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002, 347:1233-1241.
2. Poggi M, Danforth D, Sciuto L, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer 2003, 98:697-702.
3. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002, 347:1227-1232.
4. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 2011, 378:1707-1716. Early Breast Cancer Trialists' Collaborative Group.
5. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007, 25:3259-3265.
6. Overgaard M Overview of randomized trials in high risk breast cancer patients treated with adjuvant systemic therapy with or without postmastectomy irradiation. Semin Radiat Oncol 1999, 9:292-299.
7. Perou C, Sorlie T, Eisen M, et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
8. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
9. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
10. Perou CM Molecular stratification of triple-negative breast cancers. Oncologist 2010, 15(suppl 5):39-48.
11. Boyle P Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 2012, 23(suppl 6):vi7-vi12.
12. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434.
13. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423.
14. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 2007, 109:1721-1728.
15. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006, 49:22-34.
16. Carey LA PC, Livasy CA, Dressler LG, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2503.
17. Moran MS, Yang Q, Harris LN, Jones B, Tuck DP, Haffty BG Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer. Cancer 2008, 113:2565-2574.
18. Jones T, Neboori H, Wu H, et al. Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer?. Ann Surg Oncol 2013, 20:2866-2872.
19. Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 2012, 118:5463-5472.
20. Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011, 17:1082-1089.
21. Lakhani S, Reis-Filho J, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005, 11:5175-5180.
22. Foulkes WD, Smith IE, Reis-Filho JS Triple-negative breast cancer. N Engl J Med 2010, 363:1938-1948.
23. Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 2006, 12:537-544.
24. James C, Quinn J, Mullan P BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 2007, 12:142-150.
25. Scully R, Livingston DM In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000, 408:429-432.
26. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003, 21:2397-2406. American Society of Clinical Oncology.
27. Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010, 28:893-901.
28. Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010, 121:389-398.
29. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006, 24:5652-5657.
30. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008, 26:2373-2378.
31. Millar EK, Graham PH, O'Toole SA, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 2009, 27:4701-4708.
32. Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010, 28:1684-1691.
33. Billar JA, Dueck AC, Stucky CC, et al. Triple-negative breast cancers: unique clinical presentations and outcomes. Ann Surg Oncol 2010, 17(suppl 3):384-390.
34. Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 2011, 29:3885-3891.
35. Gangi A, Chung A, Mirocha J, Liou DZ, Leong T, Giuliano AE Breast-conserving therapy for triple-negative breast cancer. JAMA Surg 2014, 149:252-258.
36. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013, 31:3997-4013.
37. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
38. Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002, 20:4141-4149.
39. Romond E, Perez E, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
40. Lowery A, Kell M, Glynn R, Kerin M, Sweeney K Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat 2012, 133:831-841.
41. Wang J, Xie X, Wang X, et al. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: a meta-analysis. Surg Oncol 2013, 22:247-255.
42. Chen J, Jiang P, Wang H, et al. The efficacy of molecular subtyping in predicting postoperative recurrence in breast-conserving therapy: a 15-study meta-analysis. World J Surg Oncol 2014, 12:212.
43. Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D, Sabri S Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 2011, 29:2852-2858.
44. Steward LT, Gao F, Taylor MA, Margenthaler JA Impact of radiation therapy on survival in patients with triple-negative breast cancer. Oncol Lett 2014, 7:548-552.
45. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014, 383:2127-2135. EBCTCG (Early Breast Cancer Trialists' Collaborative Group).
46. Truong P, Olivotto I, Whelan T, Levine M Clinical practice guidelines for the care and treatment of breast cancer: 16. locoregional post-mastectomy radiotherapy. CMAJ 2004, 170:1263-1273. Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
47. Wang J, Shi M, Ling R, et al. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial. Radiother Oncol 2011, 100:200-204.
48. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013, 24:2206-2223.
49. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1539-1569.
50. Jones HA, Antonini N, Hart AA, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol 2009, 27:4939-4947.
51. Sioshansi S, Ehdaivand S, Cramer C, Lomme MM, Price LL, Wazer DE Triple negative breast cancer is associated with an increased risk of residual invasive carcinoma after lumpectomy. Cancer 2012, 118:3893-3898.
52. Rowe B, Moran MS Accelerated partial breast irradiation and hypofractionated whole breast radiation. US Oncol Hematol 2011, 7:31-37.
53. Hattangadi-Gluth JA, Wo JY, Nguyen PL, et al. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Int J Radiat Oncol Biol Phys 2012, 82:1185-1191.
54. Huang E, Buchholz TA, Meric F, et al. Classifying local disease recurrences after breast conservation therapy based on location and histology. Cancer 2002, 95:2059-2067.
55. Shaitelman SF, Vicini FA, Beitsch P, Haffty B, Keisch M, Lyden M Five-year outcome of patients classified using the American Society for Radiation Oncology consensus statement guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated on the American Society of Breast Surgeons MammoSite Registry Trial. Cancer 2010, 116:4677-4685.
56. McHaffie DR, Patel RR, Adkison JB, Das RK, Geye HM, Cannon GM Outcomes after accelerated partial breast irradiation in patients with ASTRO consensus statement cautionary features. Int J Radiat Oncol Biol Phys 2011, 81:46-51.
57. Stull TS, Goodwin CM, Gracely EJ, et al. A single-institution review of accelerated partial breast irradiation in patients considered "cautionary" by the American Society for Radiation Oncology. Ann Surg Oncol 2012, 19:553-559.
58. Pashtan IM, Recht A, Ancukiewicz M, et al. External beam accelerated partial-breast irradiation using 32 gy in 8 twice-daily fractions: 5-year results of a prospective study. Int J Radiat Oncol Biol Phys 2012, 84:e271-e277.
59. Veronesi U, Orecchia R, Luini A, et al. Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons. Breast Cancer Res Treat 2010, 124:141-151.
60. Wilkinson JB, Reid RE, Shaitelman SF, et al. Outcomes of breast cancer patients with triple negative receptor status treated with accelerated partial breast iradiation. Int J Radiat Oncol Biol Phys 2011, 81:e159-e164.
61. Wilder RB, Curcio LD, Khanijou RK, et al. Results with accelerated partial breast irradiation in terms of estrogen receptor, progesterone receptor, and human growth factor receptor 2 status. Int J Radiat Oncol Biol Phys 2010, 78:799-803.
62. Kyndi M, Sorensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008, 26:1419-1426.
63. Baeyens A, Thierens H, Claes K, Poppe B, De Ridder L, Vral A Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers. Int J Radiat Oncol Biol Phys 2004, 80:745-756.
64. Trenz K, Lugowski S, Jahrsdorfer U, Jainta S, Vogel W, Speit G Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics. Mutat Res 2003, 544:279-288.
65. Gaffney DK, Brohet RM, Lewis CM, et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 1998, 47:129-136.
66. Pierce LJ, Strawderman M, Narod SA, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 2000, 18:3360-3369.
67. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008, 26:1275-1281.
68. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767.
69. Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013, 19:5533-5540.
70. Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014, 32:2959-2967.
71. Chiorean R, Braicu C, Berindan-Neagoe I Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?. Breast 2013, 22:1026-1033.